Indications for This Combination Supplement
This combination tablet is primarily indicated as adjunctive nutritional support for conditions requiring calcium, vitamin D, and micronutrient supplementation—most commonly in the management of osteoporosis, hypoparathyroidism, chronic kidney disease-mineral bone disorder, and prevention of nutritional deficiencies in at-risk populations.
Primary Clinical Indications
Bone Health and Metabolic Bone Disease
The combination of calcium salts (1000 mg total elemental calcium from aspartate and orotate), calcitriol (0.25 mcg), and supportive minerals positions this formulation for:
Osteoporosis prevention and management in postmenopausal women and older adults who require 1200 mg daily calcium intake 1. The calcitriol dose of 0.25 mcg aligns with standard dosing for bone health support.
Hypoparathyroidism management as part of conventional therapy. Guidelines recommend calcitriol 0.25-2 mcg daily with calcium supplementation 1000-1500 mg daily 2, 3. This tablet provides appropriate starting doses for adults and children over 10 years.
X-linked hypophosphatemia (XLH) as part of conventional therapy when burosumab is unavailable. Treatment protocols specify calcitriol 0.5-1 mcg/day with adequate calcium intake 4, 5.
Nutritional Deficiency Prevention
The micronutrient profile addresses multiple deficiency states:
Post-bariatric surgery patients requiring comprehensive supplementation including calcium 1200-2000 mg daily, vitamin B12, and folic acid 6
Chronic kidney disease patients on dialysis requiring calcitriol and calcium supplementation 7
Malabsorption syndromes where combined supplementation is necessary
Component-Specific Indications
Calcitriol (0.25 mcg)
This active vitamin D dose is FDA-approved for 7:
- Hypoparathyroidism (starting dose 0.25 mcg/day)
- Dialysis patients with renal osteodystrophy (0.25 mcg every other day to 1 mcg/day)
- Predialysis chronic kidney disease
Hydroxycobalamin (100 mcg) and Folic Acid (1.5 mg)
- Megaloblastic anemia prevention in at-risk populations 8
- Post-bariatric surgery where B12 deficiency occurs in 30-40% of patients 6
- Neural tube defect prevention in women of childbearing age, though 1.5 mg exceeds standard prophylactic doses (0.4-1.0 mg) and approaches therapeutic levels 9
Zinc (7.5 mg) and Magnesium (50 mg)
- Supportive therapy for bone metabolism 10
- Glycemic control support in diabetes, particularly magnesium 11
- Prevention of deficiency in malabsorption or increased losses 1
Important Clinical Caveats
Contraindications
Do not use in patients with 7:
- Hypercalcemia
- Vitamin D toxicity
- Known hypersensitivity to calcitriol
Dosing Considerations
The 1000 mg total calcium content should be considered in context of dietary intake:
- Total daily calcium should not exceed 1500 mg from all sources 1
- Calcium absorption is optimized at ≤500-600 mg per dose, so this tablet ideally should be split if possible 1
- Calcium carbonate requires gastric acid; calcium citrate does not 1
Monitoring Requirements
Patients on this combination require:
- Serum calcium monitoring at least twice weekly during titration, then monthly 7
- 24-hour urine calcium to assess adequacy and prevent hypercalciuria 1
- Serum phosphorus and magnesium levels 2
- Renal function monitoring (creatinine, eGFR) 2
Drug Interactions
Critical interaction: The 1.5 mg folic acid dose may mask pernicious anemia while allowing neurologic damage to progress 8. Ensure adequate B12 status before initiating.
Anticonvulsant users: Both folic acid and calcium absorption may be impaired; higher doses may be needed 12. Folic acid can antagonize phenytoin's anticonvulsant effects 8.
Practical Application
This formulation is not appropriate as a standalone treatment for any condition but serves as adjunctive nutritional support. The relatively high folic acid content (1.5 mg) suggests targeting populations with increased requirements or therapeutic needs beyond simple prophylaxis, such as post-bariatric surgery patients or those with documented deficiencies requiring correction.